Is Guardant Health, Inc. (GH) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 14.3% / 30% | 10.0% / 30% | 1.2% / 30% | 3.47% / 5% | ✓ HALAL |
| DJIM | 14.3% / 33% | 10.0% / 33% | 1.2% / 33% | 3.47% / 5% | ✓ HALAL |
| MSCI | 84.9% / 33% | 59.7% / 33% | 6.8% / 33% | 3.47% / 5% | ✗ NOT HALAL |
| S&P | 14.3% / 33% | 10.0% / 33% | 1.2% / 33% | 3.47% / 5% | ✓ HALAL |
| FTSE | 84.9% / 33% | 59.7% / 33% | 6.8% / 50% | 3.47% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 64.5% | |
| Operating Margin | -42.9% | |
| Net Margin | -42.4% | |
| Return on Assets (ROA) | -15.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$185M |
| Free Cash Flow | -$233M |
| Total Debt | $1.7B |
| Current Ratio | 4.8 |
| Total Assets | $2.0B |
Price & Trading
| Last Close | $88.10 |
| 50-Day MA | $99.56 |
| 200-Day MA | $79.00 |
| Avg Volume | 1.9M |
| Beta | 1.7 |
|
52-Week Range
$36.36
| |
About Guardant Health, Inc. (GH)
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Palo Alto, California.
Purification Calculator
As a halal stock with 3.47% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Guardant Health, Inc. (GH) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Guardant Health, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Guardant Health, Inc.'s debt ratio?
Guardant Health, Inc.'s debt ratio is 14.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 84.9%.
Does Guardant Health, Inc. require dividend purification?
Yes, Guardant Health, Inc. has an impermissible income ratio of 3.47%, which means 3.47% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Guardant Health, Inc.'s key financial metrics?
Guardant Health, Inc. has a market capitalization of $11.1B, and revenue of $982M. The company maintains a gross margin of 64.5% and a net margin of -42.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.